Carl Zeiss Meditec


Healthy Q3, despite various headwinds

05/08/22 -"Despite Chinese lockdowns and supply-chain limitations, CZM managed to report healthy Q3 21/22 results. Both segments reported healthy growth, whereas the order intake was all the more impressive. ..."

Pages
57
Language
English
Published on
05/08/22
You may also be interested by these reports :
17/08/22
Demant reported soft Q2 results. While, like Sonova, the management also downgraded is full-year outlook, the brewing slowdown in the US hearing aid ...

16/08/22
After many quarters of nervousness/disappointments, Philips today announced a change in CEO, effective mid-October 2022. This was perhaps inevitable ...

16/08/22
Following Sonova and Demant’s guidance downgrades, there has been a panic across the board with all hearing aid stocks in our coverage down 4-14%. ...

11/08/22
Alcon’s Q2 results were in line with our expectations. In Q2, growth was driven by the post-Covid recovery in its target markets and the strength of ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO